Molecular Medicine |
From the Second Department of Internal Medicine (K.S., T.Y., M.K., R.N.), Gunma University School of Medicine, and Laboratory of Signal Transduction (F.O.), Institute for Molecular and Cellular Regulation, Gunma University School of Medicine, Maebashi, Japan.
Correspondence to Tomoyuki Yokoyama, MD, Second Department of Internal Medicine, Gunma University School of Medicine, 3-39-22, Showa-machi, Maebashi, 371, Japan. E-mail yokoyamt{at}news.sb.gunma-u.ac.jp
AbstractThe sphingolipid metabolites, sphingosine (SPH), SPH 1-phosphate (S1P), and sphingosylphosphorylcholine (SPC), can act as intracellular as well as extracellular signaling molecules. These compounds have been implicated in the regulation of cell growth, differentiation, and programmed cell death in nonmyocytes, but the effects of sphingolipid metabolites in cardiac myocytes are not known. Cultured neonatal rat cardiac myocytes were stimulated with SPH (1 to 10 µmol/L), S1P (1 to 10 µmol/L), or SPC (0.1 to 10 µmol/L) for 24 hours to determine the effects of sphingolipid metabolites on the rates of protein synthesis and degradation. Stimulation with SPC led to an increase in the total amount of protein, an accelerated rate of total protein synthesis, and a decrease in protein degradation in a dose-dependent manner. However, S1P had little effect and SPH had no effect on total protein synthesis. In addition, stimulation with SPC led to a 1.4-fold increase in myocardial cell size and enhanced atrial natriuretic factor gene expression. Pretreatment of the cardiac myocytes with pertussis toxin or PD98059 attenuated the SPC-induced hypertrophic growth response. Further, stimulation with SPC increased phosphorylation of mitogen-activated protein kinase (MAPK) and stimulated MAPK enzyme activity. Finally, endothelin-1 stimulated the generation of SPC in cardiac myocytes. The observation that SPC induces a hypertrophic growth response in cardiac myocytes suggests that SPC may play a critical role in the development of cardiac hypertrophy. The effects of SPC could be mediated, in part, by activation of a G proteincoupled receptor and a MAPK signaling cascade.
Key Words: sphingolipid cardiac myocyte hypertrophy receptor mitogen-activated protein kinase
This article has been cited by other articles:
![]() |
C. K. Means and J. H. Brown Sphingosine-1-phosphate receptor signalling in the heart Cardiovasc Res, May 1, 2009; 82(2): 193 - 200. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N. Lorenz, L. J. Arend, R. Robitz, R. J. Paul, and A. J. MacLennan Vascular dysfunction in S1P2 sphingosine 1-phosphate receptor knockout mice Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2007; 292(1): R440 - R446. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. French, J. J. Upson, S. N. Keller, Y. Zhuang, J. K. Yun, and C. D. Smith Antitumor Activity of Sphingosine Kinase Inhibitors J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 596 - 603. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. S. Jeon, H. Y. Song, M. R. Kim, H. J. Moon, Y. C. Bae, J. S. Jung, and J. H. Kim Sphingosylphosphorylcholine induces proliferation of human adipose tissue-derived mesenchymal stem cells via activation of JNK J. Lipid Res., March 1, 2006; 47(3): 653 - 664. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Arya, V. Kedar, J. R. Hwang, H. McDonough, H.-H. Li, J. Taylor, and C. Patterson Muscle ring finger protein-1 inhibits PKC{epsilon} activation and prevents cardiomyocyte hypertrophy J. Cell Biol., December 20, 2004; 167(6): 1147 - 1159. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Borges, J. A. Silva Jr., M. A. Gomes, E. S. L. Lomez, K. M. Leite, R. C. Araujo, M. Bader, J. B. Pesquero, and J. L. Pesquero Tonin in rat heart with experimental hypertrophy Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H2263 - H2268. [Abstract] [Full Text] [PDF] |
||||
![]() |
N C Sundgren, G D Giraud, P J S Stork, J G Maylie, and K L Thornburg Angiotensin II stimulates hyperplasia but not hypertrophy in immature ovine cardiomyocytes J. Physiol., May 1, 2003; 548(3): 881 - 891. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Cavalli, N. W. O'Brien, S. B. Barlow, R. Betto, C. C. Glembotski, P. T. Palade, and R. A. Sabbadini Expression and functional characterization of SCaMPER: a sphingolipid-modulated calcium channel of cardiomyocytes Am J Physiol Cell Physiol, March 1, 2003; 284(3): C780 - C790. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. V. Somlyo New Roads Leading to Ca2+ Sensitization Circ. Res., July 26, 2002; 91(2): 83 - 84. [Full Text] [PDF] |
||||
![]() |
T. Levade, N. Auge, R. J. Veldman, O. Cuvillier, A. Negre-Salvayre, and R. Salvayre Sphingolipid Mediators in Cardiovascular Cell Biology and Pathology Circ. Res., November 23, 2001; 89(11): 957 - 968. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sekiguchi, M. Kurabayashi, Y. Oyama, Y. Aihara, T. Tanaka, H. Sakamoto, Y. Hoshino, T. Kanda, T. Yokoyama, Y. Shimomura, et al. Homeobox Protein Hex Induces SMemb/Nonmuscle Myosin Heavy Chain-B Gene Expression Through the cAMP-Responsive Element Circ. Res., January 19, 2001; 88(1): 52 - 58. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Xu, Y.-j. Xiao, L. M. Baudhuin, and B. M. Schwartz The Role and Clinical Applications of Bioactive Lysolipids in Ovarian Cancer Reproductive Sciences, January 1, 2001; 8(1): 1 - 13. [Abstract] [PDF] |
||||
![]() |
T.-L. Yue, J.-L. Gu, C. Wang, A. D. Reith, J. C. Lee, R. C. Mirabile, R. Kreutz, Y. Wang, B. Maleeff, A. A. Parsons, et al. Extracellular Signal-regulated Kinase Plays an Essential Role in Hypertrophic Agonists, Endothelin-1 and Phenylephrine-induced Cardiomyocyte Hypertrophy J. Biol. Chem., November 22, 2000; 275(48): 37895 - 37901. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |